Charles River Laboratories International (CRL) Projected to Post Earnings on Wednesday

Charles River Laboratories International (NYSE:CRL) will likely be releasing its Q4 2025 results before the market opens on Wednesday, February 18th. Analysts expect Charles River Laboratories International to post earnings of $2.33 per share and revenue of $986.98 million for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, February 18, 2026 at 8:30 AM ET.

Charles River Laboratories International Stock Performance

NYSE:CRL opened at $161.15 on Tuesday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.10 and a current ratio of 1.37. The stock has a 50-day simple moving average of $202.74 and a two-hundred day simple moving average of $179.65. The firm has a market capitalization of $7.93 billion, a PE ratio of -103.30, a P/E/G ratio of 4.88 and a beta of 1.63. Charles River Laboratories International has a 52-week low of $91.86 and a 52-week high of $228.88.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. TD Cowen reiterated a “buy” rating on shares of Charles River Laboratories International in a research note on Thursday, January 22nd. Wall Street Zen upgraded Charles River Laboratories International from a “hold” rating to a “buy” rating in a research report on Saturday, February 7th. Morgan Stanley set a $185.00 target price on Charles River Laboratories International in a research report on Monday, December 1st. Barclays lifted their target price on Charles River Laboratories International from $210.00 to $215.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Charles River Laboratories International in a research note on Wednesday, January 21st. Ten equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $209.46.

Hedge Funds Weigh In On Charles River Laboratories International

Institutional investors have recently bought and sold shares of the business. Advisory Services Network LLC increased its holdings in shares of Charles River Laboratories International by 2.6% in the 3rd quarter. Advisory Services Network LLC now owns 3,226 shares of the medical research company’s stock worth $505,000 after buying an additional 83 shares during the last quarter. Smartleaf Asset Management LLC lifted its holdings in shares of Charles River Laboratories International by 14.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 744 shares of the medical research company’s stock valued at $150,000 after acquiring an additional 94 shares during the last quarter. Public Employees Retirement System of Ohio grew its position in Charles River Laboratories International by 0.6% in the third quarter. Public Employees Retirement System of Ohio now owns 15,240 shares of the medical research company’s stock worth $2,384,000 after acquiring an additional 95 shares in the last quarter. Brown Advisory Inc. increased its stake in Charles River Laboratories International by 5.1% during the second quarter. Brown Advisory Inc. now owns 2,333 shares of the medical research company’s stock worth $354,000 after acquiring an additional 114 shares during the last quarter. Finally, Geneos Wealth Management Inc. raised its position in Charles River Laboratories International by 98.0% during the second quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock valued at $44,000 after purchasing an additional 145 shares during the period. Institutional investors own 98.91% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.